Last reviewed 2026-04-20 · How we verify

US Neulasta

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Musculoskeletal pain
• Headache
• Vomiting
• Injection site pain
• Red blood cells urine positive
• Pyrexia
• Toothache
• Human chorionic gonadotropin increased
• Protein urine present
• Oropharyngeal pain
• Eosinophilia
• Abdominal pain

Key clinical trials

• TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (PHASE2)
• Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta (PHASE1)
• A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects (PHASE1)
• Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects. (PHASE1)
• Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects. (PHASE1)
• Safety and Immunogenicity of MSB11455 in Healthy Participants (PHASE1)
• A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers (PHASE1)
• A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.